BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 31, 2007
View Archived Issues
Pramipexole shows potential in treatment-resistant depression
Read More
Recent patents describe new therapeutic agents for diabetes
Read More
Protease-mediated CXCR1 cleavage increases infection risk in cystic fibrosis lung disease
Read More
LPA1: a novel therapeutic target for idiopathic pulmonary fibrosis
Read More
New antiinfective agents disclosed in recent patent literature
Read More
Basilea files Canadian New Drug Submission for alitretinoin for chronic hand eczema
Read More
Progen's phase III study of PI-88 for HCC open for recruitment
Read More
Diamyd files IND with FDA for phase III clinical trial of Diamyd for type 1 diabetes
Read More
Lundbeck and Paion expand license agreement for desmoteplase
Read More
Medivir and Presidio amend MIV-310 license agreement
Read More
Phase I trial commences for Cougar Biotechnology's CB-3304
Read More
AVI BioPharma starts dosing in Duchenne muscular dystrophy trial
Read More
Pharming requests re-examination of CHMP opinion for Rhucin
Read More
Eisai commences cash tender offer for outstanding MGI shares
Read More
Cubist acquires Illumigen Biosciences
Read More
Fresenius applies for marketing authorization of Removab for malignant ascites
Read More
Preliminary phase II results reported for Sinovac's pandemic influenza vaccine
Read More
Cell Therapeutics completes Zevalin's acquisition for U.S. sales and marketing
Read More
CytRx initiates phase IIb trial with arimoclomol for the treatment of ALS
Read More
Galvus obtains positive opinion regarding E.U. prescribing information changes
Read More
Endocyte and R&D-Biopharmaceuticals enter tubulysin chemo agent agreement
Read More
Collegium reports results for its abuse deterrent sustained release opioid study
Read More
Immtech's pafuramidine program on clinical hold
Read More
Antisense provides update on ATL-1102 phase IIa multiple sclerosis trial
Read More
PharmaMar's Yondelis completes requirements for launch in Spain
Read More